Introduction: Gastric cancer (GC) remains one of the most lethal malignancies worldwide, with over one million new cases diagnosed annually. Gastric carcinogenesis is a multifactorial process involving a complex interplay between environmental and host factors. Emerging evidence suggests that alterations in the gastric microbiome, including infection with Helicobacter pylori, contribute to cancer development. Notably, bacteriophages (phages) may influence tumorigenesis by modulating microbial communities, promoting the proliferation of oncogenic bacteria, and altering host-microbiota interactions. Moreover, early diagnosis of GC remains a major challenge, significantly impacting treatment efficacy and increasing mortality rates. Phages have been proposed as potential biomarkers for diseases associated with dysbiosis, due to the correlation between disease states and changes in the virome, which in turn reflect bacterial alterations. Therefore, it is crucial to deepen our understanding of the interaction between phages and the human bacteriome, as this relationship may be exploited for the early diagnosis of GC and the monitoring of carcinogenesis in the gastrointestinal tract. Objectives: This study aimed to characterize the H. pylori phage community in gastric tumor samples from patients diagnosed with GC. Methods: Tumor fragments (0.5 cm) were collected from 11 H. pylori-positive GC patients admitted to oncology reference hospitals in Pará, Brazil. RNA was extracted and sequenced using the Illumina NextSeq 500 platform. Low-quality reads and adapter sequences were removed using Trimmomatic, and read quality was assessed with FastQC. Taxonomic classification was performed using KRAKEN against a custom database of 31 complete H. pylori phage genomes obtained from GenBank. Results: A total of 11 H. pylori phages from the genus Schmidvirus were identified. The most abundant was prophage Pt-4472-G (51% of reads), followed by Pt-1293-U (14%) and Fr-B58-M (5%). Other phages included COL-23-PUJ (4%), Fr-GC43-A (3%), Pt-1846-U (2%), Pt-22899-G (2%), Pt-B92-G (2%), Pt-B89-G (1%), KHP40 (1%), Pt-5771-G (1%), and additional Schmidvirus phages (13%). These results demonstrate significant phage diversity within the tumor microenvironment. Conclusion: The presence and taxonomic diversity of H. pylori phages in gastric tumors suggest a complex virome-bacteriome interaction with potential implications for GC pathogenesis and progression. The modulation of the gastric microbiome by phages highlights their potential as biomarkers for tumor-associated dysbiosis and as candidates for the early diagnosis and monitoring of gastric cancer.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
